Does HER2 Immunoreactivity Provide Prognostic Information in Locally Advanced Urothelial Carcinoma Patients Receiving Adjuvant M-VEC Chemotherapy?

Publisher： Karger

E-ISSN： 1423-0399|79|3|210-216

ISSN： 0042-1138

Source： Urologia Internationalis, Vol.79, Iss.3, 2007-10, pp. : 210-216

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology–Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration

By  

BJU INTERNATIONAL, Vol. 121, Iss. 2, 2018-02 ,pp. : 252-259

John Wiley & Sons Inc

Access to resources Recommend Favorite

Double‐blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma

By  

CANCER, Vol. 120, Iss. 5, 2014-03 ,pp. : 692-701

John Wiley & Sons Inc

Access to resources Recommend Favorite

Neoadjuvant and Adjuvant Chemotherapy of Locally Advanced Stomach Cancer

By  

Oncology Research and Treatment, Vol. 24, Iss. 2, 2001-05 ,pp. : 116-121

Karger

Access to resources Recommend Favorite

Paclitaxel plus Doxorubicin Chemotherapy as Second-Line Therapy in Patients with Advanced Urothelial Carcinoma Pretreated with Platinum plus Gemcitabine Chemotherapy

By  

Oncology Research and Treatment, Vol. 35, Iss. 10, 2012-09 ,pp. : 576-580

Karger

Access to resources Recommend Favorite

Role of adjuvant chemotherapy for lymph node‐positive upper tract urothelial carcinoma and the prognostic significance of C‐reactive protein: A multi‐institutional, retrospective study

By  

INTERNATIONAL JOURNAL OF UROLOGY, Vol. 22, Iss. 11, 2015-11 ,pp. : 1006-1012

John Wiley & Sons Inc

Access to resources Recommend Favorite